AbbVie acquires Nimble Therapeutics, Inc.

AbbVie acquired Nimble Therapeutics, Inc. for $288 million ($210 million upfront), a transaction completed in January 2025, structured as cash upfront plus contingent consideration.

Nimble Therapeutics, Inc. operates in Immunology, is based in Madison, Wisconsin. Nimble is a biotech focused on oral peptide therapeutics; its lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, alongside a peptide synthesis, screening and optimization platform. The FY2025 10-K states an aggregate purchase price of $288 million ($210 million upfront cash plus $78 million contingent consideration).

Strengthens AbbVie's immunology pipeline and adds oral-peptide R&D capabilities.

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.